Cargando…
Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214
SIMPLE SUMMARY: To investigate a possible treatment strategy for hormone receptor (HR)-positive, HER2-negative advanced and/or metastatic breast cancer (AMBC), we investigated the clinical usefulness of adding capecitabine to maintenance endocrine therapy after induction chemotherapy and the efficac...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430728/ https://www.ncbi.nlm.nih.gov/pubmed/34503209 http://dx.doi.org/10.3390/cancers13174399 |
_version_ | 1783750771556220928 |
---|---|
author | Masuda, Norikazu Yoshinami, Tetsuhiro Ikeda, Masahiko Mizutani, Makiko Yamaguchi, Miki Komoike, Yoshifumi Takashima, Tsutomu Yoshidome, Katsuhide Tsurutani, Junji Iwamoto, Mitsuhiko Fujisawa, Fumie Yasojima, Hiroyuki Yamamura, Jun Morishima, Hirotaka Aki, Fuminori Yamada, Tomomi Morita, Satoshi Nakayama, Takahiro |
author_facet | Masuda, Norikazu Yoshinami, Tetsuhiro Ikeda, Masahiko Mizutani, Makiko Yamaguchi, Miki Komoike, Yoshifumi Takashima, Tsutomu Yoshidome, Katsuhide Tsurutani, Junji Iwamoto, Mitsuhiko Fujisawa, Fumie Yasojima, Hiroyuki Yamamura, Jun Morishima, Hirotaka Aki, Fuminori Yamada, Tomomi Morita, Satoshi Nakayama, Takahiro |
author_sort | Masuda, Norikazu |
collection | PubMed |
description | SIMPLE SUMMARY: To investigate a possible treatment strategy for hormone receptor (HR)-positive, HER2-negative advanced and/or metastatic breast cancer (AMBC), we investigated the clinical usefulness of adding capecitabine to maintenance endocrine therapy after induction chemotherapy and the efficacy of reinduction chemotherapy. Patients who had received bevacizumab–paclitaxel induction therapy and did not have progressive disease were randomized to receive maintenance therapy with endocrine therapy alone (group E; n = 46) or endocrine therapy plus capecitabine (group EC; n = 44). The median progression-free survival (PFS) under maintenance therapy (primary endpoint) was significantly longer in group EC than in group E (11.1 vs. 4.3 months; hazard ratio, 0.53; p < 0.01). At 24 months from the induction therapy start, the overall survival (OS) rate was significantly higher in group EC than in group E (83.5% vs. 62.3%; p = 0.02). Therefore, the addition of capecitabine to maintenance endocrine therapy may be a beneficial option after induction chemotherapy for HR-positive, HER2-negative AMBC patients. ABSTRACT: Optimal treatment strategies for hormone receptor (HR)-positive, HER2-negative advanced and/or metastatic breast cancer (AMBC) remain uncertain. We investigated the clinical usefulness of adding capecitabine to maintenance endocrine therapy after induction chemotherapy and the efficacy of reinduction chemotherapy. Patients who had received bevacizumab–paclitaxel induction therapy and did not have progressive disease (PD) were randomized to maintenance therapy with endocrine therapy alone (group E) or endocrine plus capecitabine (1657 mg/m(2)/day on days 1–21, q4w) (group EC). In case of PD after maintenance therapy, patients received bevacizumab–paclitaxel reinduction therapy. Ninety patients were randomized. The median progression-free survival (PFS) under maintenance therapy (primary endpoint) was significantly longer in group EC (11.1 {95% CI, 8.0–11.8} months) than in group E (4.3 {3.6–6.0} months) (hazard ratio, 0.53; p < 0.01). At 24 months from the induction therapy start, the overall survival (OS) was significantly longer in group EC than in group E (hazard ratio, 0.41; p = 0.046). No difference was found in the time to failure of strategy (13.9 and 16.6 months in groups E and EC, respectively). Increased capecitabine-associated toxicities in group EC were tolerable. Addition of capecitabine to maintenance endocrine therapy may be a beneficial option after induction chemotherapy for HR-positive, HER2-negative AMBC patients. |
format | Online Article Text |
id | pubmed-8430728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84307282021-09-11 Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214 Masuda, Norikazu Yoshinami, Tetsuhiro Ikeda, Masahiko Mizutani, Makiko Yamaguchi, Miki Komoike, Yoshifumi Takashima, Tsutomu Yoshidome, Katsuhide Tsurutani, Junji Iwamoto, Mitsuhiko Fujisawa, Fumie Yasojima, Hiroyuki Yamamura, Jun Morishima, Hirotaka Aki, Fuminori Yamada, Tomomi Morita, Satoshi Nakayama, Takahiro Cancers (Basel) Article SIMPLE SUMMARY: To investigate a possible treatment strategy for hormone receptor (HR)-positive, HER2-negative advanced and/or metastatic breast cancer (AMBC), we investigated the clinical usefulness of adding capecitabine to maintenance endocrine therapy after induction chemotherapy and the efficacy of reinduction chemotherapy. Patients who had received bevacizumab–paclitaxel induction therapy and did not have progressive disease were randomized to receive maintenance therapy with endocrine therapy alone (group E; n = 46) or endocrine therapy plus capecitabine (group EC; n = 44). The median progression-free survival (PFS) under maintenance therapy (primary endpoint) was significantly longer in group EC than in group E (11.1 vs. 4.3 months; hazard ratio, 0.53; p < 0.01). At 24 months from the induction therapy start, the overall survival (OS) rate was significantly higher in group EC than in group E (83.5% vs. 62.3%; p = 0.02). Therefore, the addition of capecitabine to maintenance endocrine therapy may be a beneficial option after induction chemotherapy for HR-positive, HER2-negative AMBC patients. ABSTRACT: Optimal treatment strategies for hormone receptor (HR)-positive, HER2-negative advanced and/or metastatic breast cancer (AMBC) remain uncertain. We investigated the clinical usefulness of adding capecitabine to maintenance endocrine therapy after induction chemotherapy and the efficacy of reinduction chemotherapy. Patients who had received bevacizumab–paclitaxel induction therapy and did not have progressive disease (PD) were randomized to maintenance therapy with endocrine therapy alone (group E) or endocrine plus capecitabine (1657 mg/m(2)/day on days 1–21, q4w) (group EC). In case of PD after maintenance therapy, patients received bevacizumab–paclitaxel reinduction therapy. Ninety patients were randomized. The median progression-free survival (PFS) under maintenance therapy (primary endpoint) was significantly longer in group EC (11.1 {95% CI, 8.0–11.8} months) than in group E (4.3 {3.6–6.0} months) (hazard ratio, 0.53; p < 0.01). At 24 months from the induction therapy start, the overall survival (OS) was significantly longer in group EC than in group E (hazard ratio, 0.41; p = 0.046). No difference was found in the time to failure of strategy (13.9 and 16.6 months in groups E and EC, respectively). Increased capecitabine-associated toxicities in group EC were tolerable. Addition of capecitabine to maintenance endocrine therapy may be a beneficial option after induction chemotherapy for HR-positive, HER2-negative AMBC patients. MDPI 2021-08-31 /pmc/articles/PMC8430728/ /pubmed/34503209 http://dx.doi.org/10.3390/cancers13174399 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Masuda, Norikazu Yoshinami, Tetsuhiro Ikeda, Masahiko Mizutani, Makiko Yamaguchi, Miki Komoike, Yoshifumi Takashima, Tsutomu Yoshidome, Katsuhide Tsurutani, Junji Iwamoto, Mitsuhiko Fujisawa, Fumie Yasojima, Hiroyuki Yamamura, Jun Morishima, Hirotaka Aki, Fuminori Yamada, Tomomi Morita, Satoshi Nakayama, Takahiro Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214 |
title | Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214 |
title_full | Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214 |
title_fullStr | Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214 |
title_full_unstemmed | Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214 |
title_short | Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214 |
title_sort | capecitabine in combination with endocrine therapy as maintenance therapy after bevacizumab plus paclitaxel induction therapy for hormone receptor-positive, her2-negative metastatic breast cancer: kbcsg-tr1214 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430728/ https://www.ncbi.nlm.nih.gov/pubmed/34503209 http://dx.doi.org/10.3390/cancers13174399 |
work_keys_str_mv | AT masudanorikazu capecitabineincombinationwithendocrinetherapyasmaintenancetherapyafterbevacizumabpluspaclitaxelinductiontherapyforhormonereceptorpositiveher2negativemetastaticbreastcancerkbcsgtr1214 AT yoshinamitetsuhiro capecitabineincombinationwithendocrinetherapyasmaintenancetherapyafterbevacizumabpluspaclitaxelinductiontherapyforhormonereceptorpositiveher2negativemetastaticbreastcancerkbcsgtr1214 AT ikedamasahiko capecitabineincombinationwithendocrinetherapyasmaintenancetherapyafterbevacizumabpluspaclitaxelinductiontherapyforhormonereceptorpositiveher2negativemetastaticbreastcancerkbcsgtr1214 AT mizutanimakiko capecitabineincombinationwithendocrinetherapyasmaintenancetherapyafterbevacizumabpluspaclitaxelinductiontherapyforhormonereceptorpositiveher2negativemetastaticbreastcancerkbcsgtr1214 AT yamaguchimiki capecitabineincombinationwithendocrinetherapyasmaintenancetherapyafterbevacizumabpluspaclitaxelinductiontherapyforhormonereceptorpositiveher2negativemetastaticbreastcancerkbcsgtr1214 AT komoikeyoshifumi capecitabineincombinationwithendocrinetherapyasmaintenancetherapyafterbevacizumabpluspaclitaxelinductiontherapyforhormonereceptorpositiveher2negativemetastaticbreastcancerkbcsgtr1214 AT takashimatsutomu capecitabineincombinationwithendocrinetherapyasmaintenancetherapyafterbevacizumabpluspaclitaxelinductiontherapyforhormonereceptorpositiveher2negativemetastaticbreastcancerkbcsgtr1214 AT yoshidomekatsuhide capecitabineincombinationwithendocrinetherapyasmaintenancetherapyafterbevacizumabpluspaclitaxelinductiontherapyforhormonereceptorpositiveher2negativemetastaticbreastcancerkbcsgtr1214 AT tsurutanijunji capecitabineincombinationwithendocrinetherapyasmaintenancetherapyafterbevacizumabpluspaclitaxelinductiontherapyforhormonereceptorpositiveher2negativemetastaticbreastcancerkbcsgtr1214 AT iwamotomitsuhiko capecitabineincombinationwithendocrinetherapyasmaintenancetherapyafterbevacizumabpluspaclitaxelinductiontherapyforhormonereceptorpositiveher2negativemetastaticbreastcancerkbcsgtr1214 AT fujisawafumie capecitabineincombinationwithendocrinetherapyasmaintenancetherapyafterbevacizumabpluspaclitaxelinductiontherapyforhormonereceptorpositiveher2negativemetastaticbreastcancerkbcsgtr1214 AT yasojimahiroyuki capecitabineincombinationwithendocrinetherapyasmaintenancetherapyafterbevacizumabpluspaclitaxelinductiontherapyforhormonereceptorpositiveher2negativemetastaticbreastcancerkbcsgtr1214 AT yamamurajun capecitabineincombinationwithendocrinetherapyasmaintenancetherapyafterbevacizumabpluspaclitaxelinductiontherapyforhormonereceptorpositiveher2negativemetastaticbreastcancerkbcsgtr1214 AT morishimahirotaka capecitabineincombinationwithendocrinetherapyasmaintenancetherapyafterbevacizumabpluspaclitaxelinductiontherapyforhormonereceptorpositiveher2negativemetastaticbreastcancerkbcsgtr1214 AT akifuminori capecitabineincombinationwithendocrinetherapyasmaintenancetherapyafterbevacizumabpluspaclitaxelinductiontherapyforhormonereceptorpositiveher2negativemetastaticbreastcancerkbcsgtr1214 AT yamadatomomi capecitabineincombinationwithendocrinetherapyasmaintenancetherapyafterbevacizumabpluspaclitaxelinductiontherapyforhormonereceptorpositiveher2negativemetastaticbreastcancerkbcsgtr1214 AT moritasatoshi capecitabineincombinationwithendocrinetherapyasmaintenancetherapyafterbevacizumabpluspaclitaxelinductiontherapyforhormonereceptorpositiveher2negativemetastaticbreastcancerkbcsgtr1214 AT nakayamatakahiro capecitabineincombinationwithendocrinetherapyasmaintenancetherapyafterbevacizumabpluspaclitaxelinductiontherapyforhormonereceptorpositiveher2negativemetastaticbreastcancerkbcsgtr1214 |